Friday, March 27, 2026 For Patients CME Credits Newsletters
Subscribe

Allergy & Immunology

3 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Barzolvolimab Phase 3 Study in Chronic Urticaria: Efficacy and Safety Under Investigation
This Phase 3 trial evaluates barzolvolimab in 963 adults with chronic spontaneous urticaria unresponsive to H1-antihistamines. The primary endpoint is the mean change in UAS7 score from baseline to We…
Researchers are studying a new drug called barzolvolimab for adults with chronic hives that are hard to control. They aim to see if this drug works better than a placebo, which is an inactive treatmen…
Phase II Trial Explores Nivolumab in High-Risk HIV-Associated Anal Cancer
This Phase II trial investigates the safety of reduced intensity CRT in low-risk HIV-associated anal cancer and nivolumab post-CRT in high-risk cases. Primary outcomes include adverse event incidence …
Researchers are testing different treatments for anal cancer linked to HIV. They are looking at how safe these treatments are and if they can help prevent cancer from returning.…
IMP2ART Pilot Shows Feasibility for Asthma Self-Management in UK Primary Care
The IMP2ART pilot cRCT demonstrated feasibility and acceptability of an asthma self-management strategy in UK primary care, with successful implementation in 6 practices.
Researchers tested a new way to help asthma patients manage their condition better in UK clinics. They found that doctors and staff were mostly positive about this new approach and participated active…
CT.gov · Phase 3 Trial Evaluates Safety and Immunogenicity of CHIKV VLP Vaccine in Childr… CT.gov · Phase 2 Study: L-SABR Plus Standard Therapy in Metastatic NSCLC Patients CT.gov · Ivonescimab Phase II Study Targets 55% DCR in Relapsed Pleural Mesothelioma CT.gov · Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCD CT.gov · Phase 2 Study: ManNAc for FSGS Shows Promise in Reducing Proteinuria CT.gov · Phase 3 Trial: Anifrolumab Shows Promise in SLE with BICLA Response as Primary O…